Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent (Q28475431)

https://www.ncbi.nlm.nih.gov/pubmed/?term=20838649

title

Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent (English)

0 references

main subject

infectious disease

0 references

India

0 references

visceral leishmaniasis

1 reference

cost-effectiveness analysis

inferred from title

1 reference

7

0 references

Shyam Sundar

4

object named as

Shyam Sundar

0 references

Piero Olliaro

3

object named as

Piero Olliaro

0 references

Manica Balasegaram

2

object named as

Manica Balasegaram

0 references

author name string

Filip Meheus

1

0 references

Suman Rijal

5

0 references

Md Abul Faiz

PLoS Neglected Tropical Diseases

6

0 references

language of work or name

English

0 references

publication date

7 September 2010

0 references

published in

0 references

volume

4

0 references

issue

9

0 references

page(s)

e818

0 references

copyright license

Creative Commons Attribution 2.5 Generic

0 references

on focus list of Wikimedia project

ScienceSource

0 references

cites work

Single-dose liposomal amphotericin B for visceral leishmaniasis in India

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2935395

Cost-effectiveness projections of single and combination therapies for visceral leishmaniasis in Bihar, India

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2935395

Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2935395

Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2935395

Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2935395

Combination therapy for visceral leishmaniasis

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2935395

Short-course paromomycin treatment of visceral leishmaniasis in India: 14-day vs 21-day treatment

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2935395

The poorest of the poor: a poverty appraisal of households affected by visceral leishmaniasis in Bihar, India

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2935395

Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, India

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2935395

New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2935395

Comparison of treatment regimens of kala-azar based on culture & sensitivity of amastigotes to sodium antimony gluconate.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2935395

Injectable paromomycin for Visceral leishmaniasis in India

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2935395

Drug policy for visceral leishmaniasis: a cost-effectiveness analysis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2935395

Liposomal amphotericin B for the treatment of visceral leishmaniasis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2935395

Serious underreporting of visceral leishmaniasis through passive case reporting in Bihar, India.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2935395

Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine).

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2935395

Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2935395

Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2935395

Oral miltefosine for Indian visceral leishmaniasis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2935395

Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2935395

A policy for leishmaniasis with respect to the prevention and control of drug resistance

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2935395

Epidemiology of visceral leishmaniasis in India

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2935395

Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2935395

Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline.

29 September 2017

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PNTD.0000818

Implementation research to support the initiative on the elimination of kala azar from Bangladesh, India and Nepal--the challenges for diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PNTD.0000818

Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PNTD.0000818

Costs of patient management of visceral leishmaniasis in Muzaffarpur, Bihar, India.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PNTD.0000818

The economic burden of visceral leishmaniasis for households in Nepal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PNTD.0000818

The economic impact of visceral leishmaniasis on households in Bangladesh

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PNTD.0000818

A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PNTD.0000818

Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PNTD.0000818

Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized phase-II clinical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PNTD.0000818

A single high dose treatment of kala-azar with Ambisome (amphotericin B lipid complex): a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PNTD.0000818

A comparative evaluation of amphotericin B and sodium antimony gluconate, as first-line drugs in the treatment of Indian visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PNTD.0000818

Availability of miltefosine for the treatment of kala-azar in India.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2935395

Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first-line drug? An observational study of 80 cases.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2935395

Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis

27 November 2018

1 reference

12 December 2020

Socio-economics of visceral leishmaniasis in Bihar (India)

1 reference

12 December 2020

Short-course of oral miltefosine for treatment of visceral leishmaniasis

1 reference

12 December 2020

Treatment of visceral leishmaniasis (kala-azar) with aminosidine (= paromomycin)-antimonial combinations, a pilot study in Bihar, India

1 reference

12 December 2020

Response to interferon-gamma plus pentavalent antimony in Indian visceral leishmaniasis

1 reference

12 December 2020

10.1371/JOURNAL.PNTD.0000818

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1413524

OpenCitations bibliographic resource ID

1413524

1 reference